prilenia

Pursuing Hope.
Leading with Science.

Prilenia is a clinical-stage biotechnology company dedicated to developing new treatments for the urgent needs facing patients and families living with Huntington's disease, ALS, and other neurodegenerative diseases and neurodevelopmental disorders.

PRIDOPIDINE

Pridopidine is a first-in-class, investigational highly selective and potent sigma-1-receptor (S1R) agonist with neuroprotective properties. It is administered by mouth in a small, easy-to-swallow capsule twice daily. Pridopidine has been studied in more than 1,650 people and long-term safety data are available from previous clinical studies, some running up to 5 years. In these investigational studies, pridopidine at the therapeutic dose has an observed safety and tolerability profile comparable to placebo.

Pridopidine is currently in late-stage development for the treatment of Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).

Prilenia is continuing the clinical and preclinical evaluation of pridopidine in various neurodegenerative diseases and neurodevelopmental disorders and plans to initiate additional clinical studies in the future.

PRIDOPIDINE PIPELINE



*Single patient, investigator-sponsored expanded access

Pridopidine is an investigational drug that has not been approved by the FDA. The safety and efficacy of pridopidine have not yet been established.

> I am moved by the **courage, resilience, and generosity of HD families**—they motivate and inspire me. I was imprinted in the early part of my career to do everything I could to alleviate some of the suffering I've seen in neurodegenerative diseases, with a special focus on HD, and that purpose continues to this day."
>
> — Michael Hayden, *CEO*